Supplemental material
Open access
3,060
Views
4
CrossRef citations to date
0
Altmetric
Report
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants
Taichi Kuramochia Chugai Pharmaceutical Co. Ltd., Fuji Gotemba Research Laboratories, Komakado, Gotemba, Shizuoka, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-7242-7124View further author information
Siok Wan Ganb Chugai Pharmabody Research Pte. Ltd., Singapore
https://orcid.org/0000-0002-6982-4492View further author information
Adrian W.S. Hob Chugai Pharmabody Research Pte. Ltd., Singapore
https://orcid.org/0000-0002-6501-5196View further author information
Bei Wangc Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR)
https://orcid.org/0000-0002-3112-7341View further author information
Nagisa Kagejid Chugai Pharmaceutical Co. Ltd., Kamakura Research Laboratories, Kajiwara, Kamakura, Kanagawa, JapanView further author information
, Takeru Nambub Chugai Pharmabody Research Pte. Ltd., SingaporeView further author information
, Sayaka Iidab Chugai Pharmabody Research Pte. Ltd., SingaporeView further author information
, Momoko Okuda-Miurab Chugai Pharmabody Research Pte. Ltd., SingaporeView further author information
, Wei Shan Chiab Chugai Pharmabody Research Pte. Ltd., SingaporeView further author information
, Chiew Ying Yeob Chugai Pharmabody Research Pte. Ltd., SingaporeView further author information
, Dan Chenb Chugai Pharmabody Research Pte. Ltd., Singapore
https://orcid.org/0000-0002-2790-5606View further author information
Wen-Hsin Leec Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR)
https://orcid.org/0000-0003-0315-7495View further author information
Eve Zi Xian Ngohc Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR)
https://orcid.org/0000-0001-5407-0280View further author information
Siti Nazihah Mohd Sallehc Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR)
https://orcid.org/0000-0002-6110-7472View further author information
Cheng-I Wangc Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR)
https://orcid.org/0000-0001-9170-2996View further author information
Tomoyuki Igawae Chugai Pharmaceutical Co. Ltd., Translational Research Division, Tokyo, JapanView further author information
& Hideaki Shimadab Chugai Pharmabody Research Pte. Ltd., Singapore
https://orcid.org/0000-0003-4932-1385View further author information
Article: 2040350
|
Received 02 Nov 2021, Accepted 07 Feb 2022, Published online: 16 Mar 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.